Esophageal Cancer Clinical Trial
Sintilimab or Placebo With Chemotherapy in Esophageal Squamous Cell Carcinoma ( ORIENT-15 )
This is a randomized, double-blind multi-center, phase III study comparing the efficacy and safety of sintilimab or placebo in combination with chemotherapy as first-line treatment in subjects with unresectable, locally advanced recurrent or metastatic esophageal squamous cell carcinoma.
After the interim analysis conducted by the iDMC, an open-label assignment of experimental arm therapy will continue in regions outside of China, in order to further evaluate the efficacy and safety of sintilimab in combination with chemotherapy in subjects representing the western population with advanced esophageal squamous cell carcinoma
Key Inclusion Criteria:
Histopathologically confirmed unresectable, locally advanced, recurrent or metastatic ESCC (excluding mixed adenosquamous carcinoma and other histological subtypes)
ECOG PS of 0 or 1
Subject must be unsuitable for definitive treatment, such as definitive chemoradiotherapy and/or surgery. For subjects who have received (neo)adjuvant or definitive chemotherapy/radiochemotherapy, time from the completion of last treatment to disease recurrence must be > 6 months Could provide archival or fresh tissues for immunotherapy-drugs-are-boosting-survival/" >PD-L1 expression analysis with obtainable results
Have at least one measurable lesion as per RECIST v1.1
Key exclusion Criteria:
ESCC with endoscopy-confirmed near-complete obstruction requiring interventional therapy
Post stent implantation in the esophagus or trachea with risk of perforation
Received systemic treatment for advanced or metastatic ESCC.
Received a cumulative dose of cisplatin ≥ 300 mg/m2 and the last cisplatin dose was within 12 months of randomization or the first dose of study treatment in the open-label phase.
High risk of hemorrhage or perforations due to tumor invasion in adjacent organs (aorta or trachea), or have fistula formation.
Hepatic metastasis > 50% of the total liver volume.
Received palliative therapy for a local lesion within 2 weeks prior to the first dose.
Received systemic treatment with Chinese traditional medicines with anti-cancer indications or immunomodulators (including thymosins, interferons, and interleukins) within 2 weeks prior to the first dose of study treatment.
Received systemic immunosuppressants within 2 weeks prior to randomization, excluding local use of glucocorticoids administered by nasal, inhaled, or other routes, and systemic glucocorticoids at physiological doses (no more than 10 mg/day of prednisone or equivalents), or glucocorticoids to prevent allergies to contrast media.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 45 Locations for this study
Anaheim California, 92835, United States
Orange California, 92868, United States
Denver Colorado, 80218, United States
Columbus Georgia, 31904, United States
Oklahoma City Oklahoma, 73104, United States
Austin Texas, 78705, United States
Vancouver Washington, 98684, United States
East Albury New South Wales, 2640, Australia
Woodville South South Australia, 5011, Australia
Heidelberg Victoria, 3079, Australia
Nedlands Western Australia, 6009, Australia
Subiaco Western Australia, 6008, Australia
Gent Corneel Heymanslaan 10, 9000, Belgium
Leuven Herestraat 49, 3000, Belgium
Bruxelles Hippocrate 10, 1200, Belgium
Brussels , 1000, Belgium
Verviers , 4800, Belgium
Beijing , , China
Bettancourt La Ferree , 25000, France
Bordeaux , 33000, France
Caen , 14000, France
Clermont Ferrand , 63000, France
Clermont Ferrand , 63100, France
Dijon , 21000, France
Dijon , 21079, France
Lille , 59020, France
Marseille , 13005, France
Paris , 75015, France
Poitiers , 86021, France
Rouen , 76000, France
Vandœuvre-lès-Nancy , 54500, France
Budapest Ráth György U. 7-9, 1122, Hungary
Nyíregyháza Szent István U. 68, 4400, Hungary
Santander Cantabria, 39008, Spain
Barcelona , 08001, Spain
Barcelona , 08035, Spain
Fuenlabrada , 28942, Spain
Girona , , Spain
Lleida , 25198, Spain
Madrid , 28040, Spain
Madrid , 28046, Spain
Madrid , , Spain
Pamplona , 31008, Spain
Sabadell , 08208, Spain
Santiago De Compostela , 15706, Spain
Sevilla , 41003, Spain
Valencia , 46016, Spain
Zaragoza , 50009, Spain
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.